Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Who Are Intolerant or Refractory to or Not Eligible for Other Cytoreductive Treatments

NCT06514807 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT06514807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06514807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Who Are Intolerant or Refractory to or Not Eligible for Other Cytoreductive Treatments
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 4, 2023
Completion date
March 15, 2028
Enrollment
117 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythaemia